Potential application of the National Kidney Foundation's chronic kidney disease guidelines in a managed care setting

American Journal of Managed Care

Volumn 10, Issue 7 I, 2004, Pages 417-422

  Thorp, Micah L ^a   Eastman, Loris ^a  

^a Kaiser Kidney Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CALCIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PROTEIN; VITAMIN D;

ANEMIA; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DIALYSIS; DISEASE COURSE; DISEASE PREDISPOSITION; GLOMERULUS FILTRATION RATE; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MANAGED CARE; MEDICAL RECORD; MORBIDITY; MORTALITY; PATIENT CARE; PATIENT EDUCATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR;

EARLY DIAGNOSIS; FOUNDATIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MANAGED CARE PROGRAMS; PRACTICE GUIDELINES; REFERRAL AND CONSULTATION; UNITED STATES;

EID: 3242816138     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey [published correction appears in Am J Kidney Dis. 2000;35:178]. Am J Kidney Dis. 1998;32:992-999.
2. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey [published correction appears in Am J Kidney Dis. 2000;35:178]. Am J Kidney Dis. 1998;32:992-999.
3. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56:2214-2219.
4. McCullough PA. Scope of cardiovascular complications in patients with kidney disease. Ethn Dis. 2002;12:S3-44-8.
5. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis. 2003;42:677-684.
6. US Renal Data System. USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 2002.
7. Keith D, Nichols G, Gullion C, Brown I, Smith D. Mortality of chronic kidney disease (CKD) in a large HMO population [abstract]. J Am Soc Nephrol. 2002;13:620A. Abstract SU-P0740.
8. EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787-1792.
9. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
10. Parving HH, Anderson AR, Smidt UM. Early aggressive antihypertensive treatment reduces rate of decline of kidney function in diabetic nephropathy. Lancet. 1983;1:1175-1179.
11. Bakris GL, Williams M, Dworkin L, et al, National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646-661.
12. Ruggenenti P, Remuzzi G. Angiotension-converting enzyme inhibitor therapy for nondiabetic progressive renal disease. Curr Opin Nephrol Hypertens. 1997;6:489-495.
13. Barrett BJ. Applying multiple interventions in chronic kidney disease. Semin Dial. 2003;16:157-164.
14. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int. 1984;25:437-444.
15. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure: an evolving disorder. Kidney Int. 1993;43:436-442.
16. Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002;137:479-486.
17. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification: part 1: executive summary. Am J Kidney Dis. 2002;39(suppl 1):S17-S31.
18. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification [published correction appears in Ann Intern Med. 2003;139:605]. Ann Intern Med. 2003;139:137-147.
19. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification [published correction appears in Ann Intern Med. 2003;139:605]. Ann Intern Med. 2003;139:137-147.
20. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28:830-838.
21. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification: part 5: evaluation of laboratory measurements for clinical assessment of kidney disease. Estimation of GFR. Am J Kidney Dis. 2002;39(suppl 1):S76-S92.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-470.
23. National Kidney Disease Education Program. Meeting on creatinine assay and reporting of estimated GFR 2003. Available at: http://www.nkdep.nih.gov. Accessed May 10, 2004.
24. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Part 4-Definition and Classification of Chronic Kidney Disease. Am J Kidney Dis. 2002;39(suppl 1):S46-S64.
25. National Kidney Foundation Web site. Available at: http://www.kidney.org. Accessed May 10, 2004.
26. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Guideline 8-Association of level of GFR with Anemia. Am J Kidney Dis. 2002;39(suppl 1):S120-S127.
27. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Guideline S-Assessment of Proteinuria. Am J Kidney Dis. 2002;39(suppl 1):S93-S102.
28. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH. Diabetic nephropathy. Diabetes Care. 2003;26(suppl 1):S94-S98.
29. Lam KSL, Cheng IKP, Janus ED, Pang RWC. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia. 1995;38:604-609.
30. Walker WG. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis. 1993;22:164-173.
31. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
32. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Guideline 10-Association of level of GFR with Bone Disease and Disorders of Calcium and Phosphate Metabolism. Am J Kidney Dis. 2002;39(suppl 1):S143-S169.
33. Holland D, Lam M. Predictors of hospitalization and death amongst predialysis patients: a retrospective study. Nephrol Dial Transplant. 2000;15: 650-658.
34. Levey AS, Greene T, Beck GJ, et al, Modification of Diet in Renal Disease Study Group. Dietary protein restriction and the progression of chronic renal disease: what have all the results of the MDRD Study shown? J Am Soc Nephrol. 1999;10:2426-2439.
35. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Guideline 9-Association of GFR with Nutritional Status. Am J Kidney Dis. 2002;39(suppl 1):S128-S142.
36. Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am J Kidney Dis. 2003;41:310-318.
37. Jungers P, Nguyen KT, Massey ZA, Man NK. Incidence of atherosclerotic cardiovascular events in patients with chronic anemia: epidemiologic studies in Ile de France. Nephrologie. 1998;19:489-494.
38. Binik YM, Devins GM, Barre PE, et al. Live and learn: patient education delays the need to initiate renal replacement therapy in end-stage renal disease. J Nerv Ment Dis. 1993;181:371-376.
39. National Kidney Foundation. Ill. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis. 2001;37(suppl 1):S137-S181.